arrow_back Back to App

More Research on Pediatric Cancer Drugs

This act aims to accelerate research into new cancer drugs, especially molecularly targeted ones, for children. This could give children with cancer faster access to innovative therapies, increasing their chances of recovery and improving their quality of life.
Key points
Requires pharmaceutical companies to conduct pediatric cancer drug investigations, even if the drug is initially for adults.
Allows for the study of combinations of active ingredients in pediatric cancer treatment, potentially leading to more effective therapies.
Ensures these investigations provide data on dosing, safety, and preliminary efficacy, tailored to children's needs.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_5416
Sponsor: Rep. Butterfield, G. K. [D-NC-1]
Process start date: 2021-09-29
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Give Kids a Chance Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_5416.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-09-29.

What are the main provisions?

Key points include:

  • Requires pharmaceutical companies to conduct pediatric cancer drug investigations, even if the drug is initially for adults.
  • Allows for the study of combinations of active ingredients in pediatric cancer treatment, potentially leading to more effective therapies.
  • Ensures these investigations provide data on dosing, safety, and preliminary efficacy, tailored to children's needs.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Butterfield, G. K. [D-NC-1].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health Family